Skyclarys, a Reata Pharmaceuticals drug, is now approved for treating the rare neuromuscular disorder Friedreich’s ataxia. The decision makes the capsule the first therapy for a disease that’s rarer than either Duchenne muscular dystrophy or spinal muscular atrophy.
The FDA told Reata that the clinical data do not show that the drug, bardoxolone, slows the progression of the loss of kidney function in patients who have the rare disease Alport syndrome. The regulatory decision follows an FDA advisory committee vote recommending against approval of the small molecule drug.
Choosing the right software translates directly into better client management, operational efficiency and growth for your spa franchise. Discover which tool is best for your business.
The Philadelphia medical center is working with a local nursing association and using technology from Vivify Health to help decrease readmission rates for liver failure patients.
One of the toughest decisions seniors and their adult children often have to make is picking a care facility. One healthcare startup confronting that challenge is Cariloop. Its service reflects the growing trend of the healthcare industry adopting services more commonly found on the likes of dating websites like Match.com or hospitality industry sites like […]